Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

BACKGROUND: Off-label use (OLU) of a drug reflects a perceived unmet medical need, which is common in oncology. Cancer drugs are often highly expensive and their reimbursement is a challenge for many healthcare systems. OLU is frequently regulated by reimbursement restrictions. For evidence-based he...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ESMO Open
Asıl Yazarlar: Herbrand, Amanda Katherina, Schmitt, Andreas Michael, Briel, Matthias, Diem, Stefan, Ewald, Hannah, Hoogkamer, Anouk, Joerger, Markus, Mc Cord, Kimberly Alba, Novak, Urban, Sricharoenchai, Sirintip, Hemkens, Lars G, Kasenda, Benjamin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2019
Konular:
Protocol
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6890379/
https://ncbi.nlm.nih.gov/pubmed/31803503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000596
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller